Long-term Follow-up Study of Patients Who Received hLB-001 Gene Therapy

Plain-language summary

This study provides long-term follow-up of patients who previously received the hLB-001 gene therapy. It enrolls patients who received hLB-001 in an earlier LogicBio clinical trial. It is a follow-up study without a phase; it is not currently recruiting but is still ongoing (active, not recruiting).

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Active, not recruiting

Sponsor

Alexion Pharmaceuticals, Inc.

Intervention

hLB-001

Start date

7/15/2022

Estimated completion

1/1/2037

Countries

United States

Related genes

Locations

• Atlanta, United States
• Pittsburgh, United States
• Nashville, United States
• Seattle, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Participant has previously participated in a LogicBio clinical trial and received hLB-001.

Exclusion Criteria:

* None